Contura International Ltd’s novel injectable treatment for knee osteoarthritis (OA), Arthrosamid ®, was officially launched at the 2021 British Orthopedic Association (BOA) Annual Congress. The innovative, long acting, and minimally invasive treatment has the potential to change the present care landscape for managing OA, harnessing non-biodegradable hydrogel technology to improve mobility and alleviate pain.
Arthrosamid® is administered as a single treatment 6 ml dose injected directly into the knee joint space, cushioning the joint and easing OA-related pain within days. The innovation of the injectable hydrogel, consisting of 2.5% cross-linked polyacrylamide and 97.5% non-pyrogenic water, allows not only for relief of symptoms of OA, but may additionally delay or forestall the need for more invasive knee surgeries for the millions of Europeans affected by the condition.